• Fennec Pharmaceuticals posted USD 201,000 net income for Q1 2026, swinging from a loss a year earlier as net sales climbed 72.64% to USD 15.11 million.
• Operating loss narrowed to USD 119,000 from USD 808,000, while total operating expense rose to USD 15.23 million on selling and marketing costs of USD 11.42 million.
• General and administrative expense fell to USD 3.19 million, while cash and equivalents increased to USD 40.18 million.
• Settlement with Cipla delays U.S. generic sodium thiosulfate entry until Sept. 1, 2033, or earlier under specified circumstances.
• Norgine launched PEDMARQSI in Germany and U.K. in 2025, with additional European launches expected in 2026; Japan registration strategy advanced following positive STS-J01 topline results announced in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-061213), on May 14, 2026, and is solely responsible for the information contained therein.